logo-loader
NeuroRx

NeuroRx aims to tackle suicide by treating bipolar depression with new therapy

NeuroRx Inc CEO Dr. Jonathan Javitt tells Proactive Investors the privately-held clinical stage biopharma company is focused on preventing suicide by treating bipolar depression with its small molecule oral drug called NRX-101.

Dr. Javitt says NRX-101 was recently granted Breakthrough Therapy Designation by the FDA for this indication, and is now entering Phase 3 clinical studies with the drug.

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Alchemist sees big market in China for medical cannabis sales

Alchemist (CSE: AMS) CEO Paul Mann and Vice President of Business Development, Asia Pacific Johnson Lee joined Steve Darling from Proactive Vancouver to discuss Alchemist looking for opportunities for cannabis in the emerging cannabis market.  Mann and Lee talk about what the industry...

1 day, 15 hours ago

2 min read